Autopsy report · NCT03285607

MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer

“Drug provider decided not to move forward with the study.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Washington University School of Medicine

Sponsor type

University, hospital or other

Conditions

Breast Cancer; Cancer of Breast

Interventions

MCS110; Doxorubicin; Cyclophosphamide; Paclitaxel; Bone marrow aspirate; Peripheral blood samples

Participants

0

Trials that died the same way

• Iontophoresis in Psoriasis
  “FDA did not provide approval of the use of the drug for the study” (72% match in meaning)
• Biopsy Collection for Men Undergoing Brachytherapy for Prostate Cancer
  “The study team decided to not move forward with enrolling patients because funding was not identified to support the project.” (70% match in meaning)
• Genes Mutation Pentalogy of Cantrell
  “Physician's chose to not follow through with the study.” (70% match in meaning)
• Panobinostat/Velcade in Multiple Myeloma
  “This study was terminated because the drug company stopped making the study drug” (70% match in meaning)
• Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction
  “The study team decided not to pursue this study.” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.